Document Detail


Current and future treatment options for nonexudative and exudative age-related macular degeneration.
MedLine Citation:
PMID:  15631528     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Age-related macular degeneration (AMD) is the leading cause of irreversible visual loss in the industrialised world. Although relatively simple to diagnose through direct visualisation augmented with rapid sequence fluorescein angiography, treatment has presented a far greater challenge because the true aetiology of AMD is largely unknown. Within the past decade, researchers have introduced many new, potentially promising treatment and prevention options in an attempt to minimise the damage imparted from AMD. They capitalise on many of the theoretical and known factors contributing to AMD progression. A high-dose of an orally administered combination of the antioxidants ascorbic acid (vitamin C), tocopherol (vitamin E) and beta-carotene, in addition to copper and zinc, is the only widely accepted preventive therapy. Thermal laser photocoagulation and verteporfin photodynamic therapy are the only standard treatment options available based on large scale, randomised, prospective, placebo-controlled trials; however, efficacy is limited and only a minority of patients who present with AMD are eligible for these treatments. Many other preventive and treatment options are in all phases of clinical studies and expected to change the entire approach to AMD management in the near future. For example, alternative antioxidants, drusen ablation, apheresis and HMG-CoA reductase inhibitors have shown promise in some studies by preventing or slowing the progression of certain forms of AMD. In addition, alternative photodynamic therapies, low-intensity laser, antiangiogenic medications, radiation treatment and surgery have demonstrated the ability, albeit to differing degrees, to inhibit or possibly even reverse the severe vision loss often associated with AMD characterised by choroidal neovascularisation.
Authors:
Grant M Comer; Thomas A Ciulla; Mark H Criswell; Michael Tolentino
Related Documents :
23724748 - Managing epididymo-orchitis in general practice.
24630418 - Percutaneous suprapubic tube after robotic assisted radical prostatectomy: true or plac...
3786278 - Antithrombotic therapy for cerebrovascular disease. prevention and treatment of stroke.
16898578 - Treatment of hypertriglyceridemia.
22751028 - Combination of pregabalin and dexamethasone for postoperative pain and functional outco...
10475598 - Pain in children with significant neurological impairment.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Drugs & aging     Volume:  21     ISSN:  1170-229X     ISO Abbreviation:  Drugs Aging     Publication Date:  2004  
Date Detail:
Created Date:  2005-01-05     Completed Date:  2005-04-06     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9102074     Medline TA:  Drugs Aging     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  967-92     Citation Subset:  IM    
Affiliation:
Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aging / physiology*
Exudates and Transudates / physiology
Humans
Macular Degeneration / diagnosis,  drug therapy,  pathology,  radiotherapy,  therapy*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polycyclic aromatic hydrocarbons in smoke used to smoke cheese produced by the combustion of rock ro...
Next Document:  Perioperative pharmacotherapy in patients with left ventricular assist devices.